I would think Dr Patrick Soon....would want such cost savings and to secure PS Targeting under the umbrella of one of his many biotech startups or create a new one...
Just another possible option / path for Peregrine, and he is one that would probably want the rs to happen but I would think they can come up with a creative plan
Maybe Sean Parker should just make a move and don't let any more time go to waste.....all of Parker Institute will need PS Targeting
I think running one test to rule out cancer would be important. If negative great. If positive, run other tests to determine which type cancer it might be.
I'd be very interested in hearing from the science guys about what competition there is in the exome-based testing area. It certainly looks like PPHM could have a slam dunk here, but are there other tests in the works that might be as good?
With respect to exosome testing, PPHM has published "Highly Specific PET Imaging of Prostate Tumors in Mice with an Iodine-124-Labeled Antibody Fragment That Targets Phosphatidylserine."
Images of tumor location show clearly in a PET scan. Any metastases should also be evident in a scan.
Exosome test tells doctors/patients that there is a significant quantum of PS-positive exosomes in the patient's system. The next step would be a conformational and locational scan.
Peregrine ran a human trial at Washington University School of Medicine, started June 2012, and closed out on schedule, March 2016. Peregrine has that data.
"Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors"
The high value of the "Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies" is the ability to diagnose this ovarian tumor type at an earlier stage than has been previously possible. It should be a real lifesaver for many women in the future of ovarian oncology.
Market Data 
Markets 
AI
